Teona Albertovna Shvangiradze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Teona Albertovna Shvangiradze has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina Anatolyevna Troshina
Endocrinology Research Centre
4 shared publications - Irina Ziyatovna Bondarenko
Endocrinology Research Centre
2 shared publications - Larisa V. Nikankina
Endocrinology Research Centre
2 shared publications - Marina Vladimirovna Shestakova
Endocrinology Research Centre, 117292 Moscow, Russia
2 shared publications Aleksandr V Karpukhin
1 shared publicationAlexander V Ilyin
1 shared publication
Latest Publications
- Open Access
- 21 December 2019
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 16 (3) , 55-61
Angiotensin II and transforming growth factor β affect cardiovascular and renal disease in patients with type 2 diabetes mellitus: benefits of dpp-4 inhibitors treatment
BACKGROUND: Diabetes mellitus type 2 (T2DM) is associated with impaired glucose metabolism and peripheral insulin resistance, which is accompanied by an high risk of cardiovascular disease (CVD) and nephropathy. Metabolic syndrome and T2DM are accompanied by renin-angiotensin system (RAS) activation, which is also associated with increased risk of CVD and kidney damage. Obesity lead to a wide range of pathophysiological changes, that stimulate cardiac fibrosis, and various fibrosis processes initiation, including activation of transforming growth factor (TGF-). AIMS: To determine activity of angiotensin II (Ang II) and TGF- in patients with obesity and T2DM and their association with heart and kidney damage. MATERIALS AND METHODS: Ang II and TGF- were identified in the peripheral blood of 66 obese patients aged 48-65 years. The first group included 21 patients with coronary heart disease (CHD) and T2DM; The second group included 22 patients with T2DM and excluded CHD; The third group 20 patients with normal glucose metabolism and excluded CHD. RESULTS: The values of TGF- in the 1st group (patients with CHD) were statistically lower than in the group of metabolically healthy obesity (p=0.021). Patients who received DPP-4 inhibitors had a lower Ang II level compared to patients with other hypoglycemic therapy (p=0.005). TGF- positively correlated with glomerular filtration rate (eGFR) in all patients (r=-0.414, p=0.006). TGF- negatively correlated with the degree of internal carotid artery stenosis in patients of the 2nd group (r=-0.42, p=0.09) and LDL-cholesterol in all patients (r=-0.426, p=0.038). CONCLUSIONS: TGF- negatively correlated with the factors that contribute to CVD progression. TGF- correlated with pathological angiogenesis and changes in normal cardiac geometry in obesity, T2DM and CHD. DPP-4 inhibitors can improve the cardiovascular prognosis in this group of patients by affecting Ang II level. Low levels of TGF- were associated with higher cardiovascular risk and were commonly found in patients with more severe nephropathy.
- 21 December 2019
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 16 (3) , 55-61
Open AccessAngiotensin II and transforming growth factor β affect cardiovascular and renal disease in patients with type 2 diabetes mellitus: benefits of dpp-4 inhibitors treatment
BACKGROUND: Diabetes mellitus type 2 (T2DM) is associated with impaired glucose metabolism and peripheral insulin resistance, which is accompanied by an high risk of cardiovascular disease (CVD) and nephropathy. Metabolic syndrome and T2DM are accompanied by renin-angiotensin system (RAS) activation, which is also associated with increased risk of CVD and kidney damage. Obesity lead to a wide range of pathophysiological changes, that stimulate cardiac fibrosis, and various fibrosis processes initiation, including activation of transforming growth factor (TGF-). AIMS: To determine activity of angiotensin II (Ang II) and TGF- in patients with obesity and T2DM and their association with heart and kidney damage. MATERIALS AND METHODS: Ang II and TGF- were identified in the peripheral blood of 66 obese patients aged 48-65 years. The first group included 21 patients with coronary heart disease (CHD) and T2DM; The second group included 22 patients with T2DM and excluded CHD; The third group 20 patients with normal glucose metabolism and excluded CHD. RESULTS: The values of TGF- in the 1st group (patients with CHD) were statistically lower than in the group of metabolically healthy obesity (p=0.021). Patients who received DPP-4 inhibitors had a lower Ang II level compared to patients with other hypoglycemic therapy (p=0.005). TGF- positively correlated with glomerular filtration rate (eGFR) in all patients (r=-0.414, p=0.006). TGF- negatively correlated with the degree of internal carotid artery stenosis in patients of the 2nd group (r=-0.42, p=0.09) and LDL-cholesterol in all patients (r=-0.426, p=0.038). CONCLUSIONS: TGF- negatively correlated with the factors that contribute to CVD progression. TGF- correlated with pathological angiogenesis and changes in normal cardiac geometry in obesity, T2DM and CHD. DPP-4 inhibitors can improve the cardiovascular prognosis in this group of patients by affecting Ang II level. Low levels of TGF- were associated with higher cardiovascular risk and were commonly found in patients with more severe nephropathy.
- Open Access
- 13 November 2017
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 14 (3) , 38-42
TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity
Backgraund: Obesity and type 2 diabetes mellitus (T2DM) are associated with with an increased risk of cardiovascular disease (CVD) and coronary artery disease (CAD), in particular. Obesity lead to several fibrotic processes, including activation of transforming growth factor (TGF-). Recent data indicate the involvement of Fibroblast growth factor 21 (FGF-21) as an important metabolic regulator, and even biomarker of metabolic changes in obesity and T2DM. Impact of metabolic dysregulation that accompany obesity and T2DM in CAD development remain a great challenge. Aims: To study TGF- and FGF-21 level in patients with obesity and T2DM. Materials and methods: TGF- and FGF-21 were identified in peripheral blood samples of 66 patients with obesity, aged 48-65 years. 1st group included 21 patients with CHD and T2DM; 2nd group (22 patients)- with T2DM and excluded CHD; 3rd group (20 patients) with normal glucose metabolism and excluded CHD. Results: TGF- was lower in patients with CHD (group 1) than in the group of "metabolically healthy" obesity (p=0.022). TGF- in patients with T2DM negatively correlated with LDL cholesterol (r=-0.426, p=0.038) the degree of internal carotid artery stenosis (r=-0.426, p=0.024). Patients with verified CHD had a negative correlation with the processes of heart muscle remodeling (thickness of the left ventricular posterior wall (r=- 0.386, p=0.029) interventricular septum (r=-0.335, p=0.031). All patients with obesity had significantly increased level of FGF-21 compared with the control group (p=0.031) FGF-21 positively correlated with BMI (r=0.473, p=0.033) Conclusions: TGF- has negative correlations with the factors that can influence prognosis and the severity of the CVD/. There were found correlations of FGF-21, TGF- with pathological angiogenesis and changes in normal cardiac geometry in obesity, T2DM and CAD.
- 13 November 2017
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 14 (3) , 38-42
Open AccessTGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity
Backgraund: Obesity and type 2 diabetes mellitus (T2DM) are associated with with an increased risk of cardiovascular disease (CVD) and coronary artery disease (CAD), in particular. Obesity lead to several fibrotic processes, including activation of transforming growth factor (TGF-). Recent data indicate the involvement of Fibroblast growth factor 21 (FGF-21) as an important metabolic regulator, and even biomarker of metabolic changes in obesity and T2DM. Impact of metabolic dysregulation that accompany obesity and T2DM in CAD development remain a great challenge. Aims: To study TGF- and FGF-21 level in patients with obesity and T2DM. Materials and methods: TGF- and FGF-21 were identified in peripheral blood samples of 66 patients with obesity, aged 48-65 years. 1st group included 21 patients with CHD and T2DM; 2nd group (22 patients)- with T2DM and excluded CHD; 3rd group (20 patients) with normal glucose metabolism and excluded CHD. Results: TGF- was lower in patients with CHD (group 1) than in the group of "metabolically healthy" obesity (p=0.022). TGF- in patients with T2DM negatively correlated with LDL cholesterol (r=-0.426, p=0.038) the degree of internal carotid artery stenosis (r=-0.426, p=0.024). Patients with verified CHD had a negative correlation with the processes of heart muscle remodeling (thickness of the left ventricular posterior wall (r=- 0.386, p=0.029) interventricular septum (r=-0.335, p=0.031). All patients with obesity had significantly increased level of FGF-21 compared with the control group (p=0.031) FGF-21 positively correlated with BMI (r=0.473, p=0.033) Conclusions: TGF- has negative correlations with the factors that can influence prognosis and the severity of the CVD/. There were found correlations of FGF-21, TGF- with pathological angiogenesis and changes in normal cardiac geometry in obesity, T2DM and CAD.
- Open Access
- 29 December 2016
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 13 (4) , 34-38
Profile of microRNAs associated with coronary heart disease in patients with type 2 diabetes
Introduction. Cardiovascular disease (CVD) remain the leading cause of death in industrialized countries. Patients with coronary heart disease (CHD) in combination with diabetes mellitus type 2 (T2DM) are characterized by more severe CHD and poor prognosis. Resent data indicate microRNAs (miRNAs) as important participants in the pathogenesis of various pathological conditions, including obesity, T2DM and CVD.The aim of this study was to determine expression of miRNAs associated with the development of CHD, and transforming growth factor beta (TGF-β) in a patients with T2DM and obesity Materials and methods. 42 patients with 1-2 degrees obesity and diagnosed T2DM were divided into 2 groups. The first group with CHD, the second group - without CHD. 9 miRNAs were evaluated: miRNA-1, miRNA-21, miRNA-26a, m miRNA-27, miRNA-33a, miRNA-33b, miRNA-133a, miRNA-133b, miRNA-208.Results and discussion. Significant differences were found in expression of miRNA-21, miRNA-26a, miRNA27a. An increased expression of miRNA-21, miRNA-27a was found in patients CHD while the expression of miRNA-26a was reduced in comparison with the group without CHD.Conclusion. The results of this study may be an initial step for the detection of molecular basis in CHD pathogenesis in these patients by quantifying miRNA expression. Introduction. Cardiovascular disease (CVD) remain the leading cause of death in industrialized countries. Patients with coronary heartdisease (CHD) in combination with diabetes mellitus type 2 (T2DM) are characterized by more severe CHD and poor prognosis. Resent data indicate microRNAs (miRNAs) as important participants in the pathogenesis of various pathological conditions, including obesity, T2DM and CVD.The aim of this study was to determine expression of miRNAs associated with the development of CHD, and transforming growth factor beta (TGF-β) in a patients with T2DM and obesity Materials and methods. 42 patients with 1-2 degrees obesity and diagnosed T2DM were divided into 2 groups. The first group with CHD, the second group - without CHD. 9 miRNAs were evaluated: miRNA-1, miRNA-21, miRNA-26a, m miRNA-27, miRNA-33a, miRNA-33b, miRNA-133a, miRNA-133b, miRNA-208.Results and discussion. Significant differences were found in expression of miRNA-21, miRNA-26a, miRNA27a. An increased expression of miRNA-21, miRNA-27a was found in patients CHD while the expression of miRNA-26a was reduced in comparison with the group without CHD.Conclusion. The results of this study may be an initial step for the detection of molecular basis in CHD pathogenesis in these patients by quantifying miRNA expression.
- 29 December 2016
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 13 (4) , 34-38
Open AccessProfile of microRNAs associated with coronary heart disease in patients with type 2 diabetes
Introduction. Cardiovascular disease (CVD) remain the leading cause of death in industrialized countries. Patients with coronary heart disease (CHD) in combination with diabetes mellitus type 2 (T2DM) are characterized by more severe CHD and poor prognosis. Resent data indicate microRNAs (miRNAs) as important participants in the pathogenesis of various pathological conditions, including obesity, T2DM and CVD.The aim of this study was to determine expression of miRNAs associated with the development of CHD, and transforming growth factor beta (TGF-β) in a patients with T2DM and obesity Materials and methods. 42 patients with 1-2 degrees obesity and diagnosed T2DM were divided into 2 groups. The first group with CHD, the second group - without CHD. 9 miRNAs were evaluated: miRNA-1, miRNA-21, miRNA-26a, m miRNA-27, miRNA-33a, miRNA-33b, miRNA-133a, miRNA-133b, miRNA-208.Results and discussion. Significant differences were found in expression of miRNA-21, miRNA-26a, miRNA27a. An increased expression of miRNA-21, miRNA-27a was found in patients CHD while the expression of miRNA-26a was reduced in comparison with the group without CHD.Conclusion. The results of this study may be an initial step for the detection of molecular basis in CHD pathogenesis in these patients by quantifying miRNA expression. Introduction. Cardiovascular disease (CVD) remain the leading cause of death in industrialized countries. Patients with coronary heartdisease (CHD) in combination with diabetes mellitus type 2 (T2DM) are characterized by more severe CHD and poor prognosis. Resent data indicate microRNAs (miRNAs) as important participants in the pathogenesis of various pathological conditions, including obesity, T2DM and CVD.The aim of this study was to determine expression of miRNAs associated with the development of CHD, and transforming growth factor beta (TGF-β) in a patients with T2DM and obesity Materials and methods. 42 patients with 1-2 degrees obesity and diagnosed T2DM were divided into 2 groups. The first group with CHD, the second group - without CHD. 9 miRNAs were evaluated: miRNA-1, miRNA-21, miRNA-26a, m miRNA-27, miRNA-33a, miRNA-33b, miRNA-133a, miRNA-133b, miRNA-208.Results and discussion. Significant differences were found in expression of miRNA-21, miRNA-26a, miRNA27a. An increased expression of miRNA-21, miRNA-27a was found in patients CHD while the expression of miRNA-26a was reduced in comparison with the group without CHD.Conclusion. The results of this study may be an initial step for the detection of molecular basis in CHD pathogenesis in these patients by quantifying miRNA expression.
- Open Access
- 15 October 2016
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 88 (10) , 87-92
MiRNAs in the diagnosis of cardiovascular diseases associated with type 2 diabetes mellitus and obesity
Worldwide, the number of patients with type 2 diabetes mellitus (T2DM), obesity, and cardiovascular diseases (CVD) continues to increase steadily. Despite long-term studies of obesity and concomitant diseases, the molecular genetic bases for the development of these pathological conditions have remained the subject of numerous investigations so far. Recent investigations point to the involvement of miRNAs as dynamic modifiers of the pathogenesis of various pathological conditions, including obesity, T2DM, and CVD. MicroRNAs are involved in various biological processes underlying the development of CVDs, including endothelial dysfunction, cell adhesion, and atherosclerotic plaque formation and rupture. Some of them are considered as potential sensitive diagnostic markers of coronary heart disease and acute myocardial infarction. Approximately 1,000 microRNAs are found in the human body. It has been determined that miRNAs regulate 30% of all human genes. Among them there are about 50 circulating miRNAs presumably associated with cardiovascular diseases. This review provides recent data on the participation of some miRNAs in various pathological and physiological states associated with CVD in DM and obesity. An extended and exact understanding of the function of miRNAs in the gene regulatory networks associated with cardiovascular risk in obesity will be able to reveal new mechanisms for the progression of disease, to predict its development, and to elaborate innovative therapeutic strategies.
- 15 October 2016
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 88 (10) , 87-92
Open AccessMiRNAs in the diagnosis of cardiovascular diseases associated with type 2 diabetes mellitus and obesity
Worldwide, the number of patients with type 2 diabetes mellitus (T2DM), obesity, and cardiovascular diseases (CVD) continues to increase steadily. Despite long-term studies of obesity and concomitant diseases, the molecular genetic bases for the development of these pathological conditions have remained the subject of numerous investigations so far. Recent investigations point to the involvement of miRNAs as dynamic modifiers of the pathogenesis of various pathological conditions, including obesity, T2DM, and CVD. MicroRNAs are involved in various biological processes underlying the development of CVDs, including endothelial dysfunction, cell adhesion, and atherosclerotic plaque formation and rupture. Some of them are considered as potential sensitive diagnostic markers of coronary heart disease and acute myocardial infarction. Approximately 1,000 microRNAs are found in the human body. It has been determined that miRNAs regulate 30% of all human genes. Among them there are about 50 circulating miRNAs presumably associated with cardiovascular diseases. This review provides recent data on the participation of some miRNAs in various pathological and physiological states associated with CVD in DM and obesity. An extended and exact understanding of the function of miRNAs in the gene regulatory networks associated with cardiovascular risk in obesity will be able to reveal new mechanisms for the progression of disease, to predict its development, and to elaborate innovative therapeutic strategies.
- Open Access
- 10 August 2015
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 12 (3) , 53
Profile of microRNAs in human adipocytes and macrophages in inflammation
Профиль микроРНК в адипоцитах и макрофагах человека при воспалении
- 10 August 2015
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 12 (3) , 53
Open AccessProfile of microRNAs in human adipocytes and macrophages in inflammation
Профиль микроРНК в адипоцитах и макрофагах человека при воспалении
- Open Access
- 10 August 2015
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 12 (3) , 54
Metformin reduces energy consumption and increases satiety in obese children
Metformin reduces energy consumption and increases satiety in obese children
- 10 August 2015
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 12 (3) , 54
Open AccessMetformin reduces energy consumption and increases satiety in obese children
Metformin reduces energy consumption and increases satiety in obese children
- Open Access
- 27 June 2015
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 12 (2) , 50
Gene Expression Analysis of Murine Brown and Subcutaneous Adipose Tissue: Significance with Human
Gene Expression Analysis of Murine Brown and Subcutaneous Adipose Tissue: Significance with Human
- 27 June 2015
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 12 (2) , 50
Open AccessGene Expression Analysis of Murine Brown and Subcutaneous Adipose Tissue: Significance with Human
Gene Expression Analysis of Murine Brown and Subcutaneous Adipose Tissue: Significance with Human
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
The functional parameters of renin-angiotensin-aldosterone system in obese patients
Introduction: Renin-angiotensin-aldosterone system (RAAS) plays a significant role in the development of arterial hypertension (AH) in obese patient. Angiotensinogen expression in adipose tissue decreases during fasting and increases in case of overeating, that leads to changes in blood pressure (BP). The aim of the study was to assess the impact of obesity on the activity of RAAS and its role in the development of hypertension. Methods: 60 women, mean age 28.0±2.1 years, BMI 37.7±1.2 kg/m2 participated in the study. Subjects were divided into groups depending of the AH presence: the 1st group consisted of 28 women with normal BP (systolic BP 115.6±1.28 mm Hg; diastolic 81.0±3.0 mm Hg). 32 women with AH (systolic BP 166.6±5.4 mm Hg; diastolic BP 96.0±3.2 mm Hg) were included in the 2nd group. 15 healthy normal weight women (19–25 years old, BMI 10.4±2.3 kg/m2) were included in the control group. NaCl consumption not + and K+ concentrations were normal. Urinary potassium excretion did not differ significantly from the control group (P>0.05), sodium excretion was significantly decreased (PPP<0.05). Conclusions: 1. Plasma aldosterone concentration in the morning hours was elevated in the obese patients without hypertension. 2. Obese hypertensive patients had inverse aldosterone biorhythm with maximum at midnight.
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
The functional parameters of renin-angiotensin-aldosterone system in obese patients
Introduction: Renin-angiotensin-aldosterone system (RAAS) plays a significant role in the development of arterial hypertension (AH) in obese patient. Angiotensinogen expression in adipose tissue decreases during fasting and increases in case of overeating, that leads to changes in blood pressure (BP). The aim of the study was to assess the impact of obesity on the activity of RAAS and its role in the development of hypertension. Methods: 60 women, mean age 28.0±2.1 years, BMI 37.7±1.2 kg/m2 participated in the study. Subjects were divided into groups depending of the AH presence: the 1st group consisted of 28 women with normal BP (systolic BP 115.6±1.28 mm Hg; diastolic 81.0±3.0 mm Hg). 32 women with AH (systolic BP 166.6±5.4 mm Hg; diastolic BP 96.0±3.2 mm Hg) were included in the 2nd group. 15 healthy normal weight women (19–25 years old, BMI 10.4±2.3 kg/m2) were included in the control group. NaCl consumption not + and K+ concentrations were normal. Urinary potassium excretion did not differ significantly from the control group (P>0.05), sodium excretion was significantly decreased (PPP<0.05). Conclusions: 1. Plasma aldosterone concentration in the morning hours was elevated in the obese patients without hypertension. 2. Obese hypertensive patients had inverse aldosterone biorhythm with maximum at midnight.
- Open Access
- 14 December 2014
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 11 (4) , 64
orlistat improves release of gut hormones increasing satiety in obese women
Orlistat, which reduces fat absorption by inhibiting intestinal lipase is a registered drug for obesity pharmacotherapy. Meta-analyzes indicate various positive metabolic effects of orlistat, including improvements in glucose and lipid metabolism, lowering both systolic and diastolic blood pressure. It is assumed that orlistat can reduce postprandial satiety by inhibiting the release of intestinal hormones (incretins), especially glucagon-like peptide-1 (GLP-1). Impact analysis of the secretion of incretins, with prolonged use of orlistat was conducted. The aim of the study M.Olszanecka-Glinianowicz et al. was to evaluate the effect of 8 weeks of treatment with orlistat as part of a weight loss program for preprandialnye levels of peptide YY and GLP-1.
- 14 December 2014
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 11 (4) , 64
Open Accessorlistat improves release of gut hormones increasing satiety in obese women
Orlistat, which reduces fat absorption by inhibiting intestinal lipase is a registered drug for obesity pharmacotherapy. Meta-analyzes indicate various positive metabolic effects of orlistat, including improvements in glucose and lipid metabolism, lowering both systolic and diastolic blood pressure. It is assumed that orlistat can reduce postprandial satiety by inhibiting the release of intestinal hormones (incretins), especially glucagon-like peptide-1 (GLP-1). Impact analysis of the secretion of incretins, with prolonged use of orlistat was conducted. The aim of the study M.Olszanecka-Glinianowicz et al. was to evaluate the effect of 8 weeks of treatment with orlistat as part of a weight loss program for preprandialnye levels of peptide YY and GLP-1.